Trial Profile

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary)
Indications Hypertrophic cardiomyopathy
Focus Registrational; Therapeutic Use
Acronyms ODYSSEY-HCM
Sponsors Bristol-Myers Squibb; MyoKardia

Most Recent Events

14 Apr 2025 Primary endpoint (Change from baseline in peak oxygen consumption (pVO2) at Week 48) has not been met.
14 Apr 2025 Primary endpoint (Change from baseline in Kansas City Cardiomyopathy Questionnaire (23-item) Clinical Summary Score (KCCQ-23 CSS) at Week 48) has not been met.
14 Apr 2025 Results published in the Bristol Myers Squibb Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com